CD8A and primary cutaneous T-cell non-Hodgkin lymphoma: In pancreatic adenocarcinoma, urothelial bladder carcinoma, and cutaneous T-cell lymphoma, LAMP3+ DCs also promote immune tolerance and immunosuppression through interacting with CD8+T or tumor-infiltrating Tregs (33–35).